Nathan J. Dowden

Nathan J. Dowden

President and Chief Operating OfficeratEntrada Therapeutics· In proxies 2022–2025

Pay in FY2024+66% from the year before · Entrada Therapeutics stock +14.6% the same year

Nathan J. Dowden was paid $2.5M in FY2024 (Dec), up 66%. Entrada Therapeutics stock rose 14.6% that year.

Pay$100 in the stock at the end of FY21 → $101
Pay is from the Summary Compensation Table of each Entrada Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Entrada TherapeuticsPublic company · 4 yr
    • President and Chief Operating Officer2022 – Present · 4 yrStock in role -73%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?